New Competition, Procedure Declines Challenge Abbott Vascular In Second Quarter
This article was originally published in The Gray Sheet
Executive Summary
Abbott’s stent business was up against an approximately 5% decline in U.S. percutaneous coronary intervention procedures in the past quarter, on top of persistent pricing pressures and the U.S. launch earlier this year of Medtronic’s Resolute Integrity.
You may also be interested in...
Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J And Novartis (Part 3)
In Part 3 of our feature, we take a closer look at the first quarterly calls for Abbott and AbbVie after the company split in two, plus the latest on emerging markets from J&J and Novartis.
Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J And Novartis (Part 3)
In Part 3 of our feature, we take a closer look at the first quarterly calls for Abbott and AbbVie after the company split in two, plus the latest on emerging markets from J&J and Novartis.
New Products In Brief
A drug-eluting stent and prostate cancer assay are among newly approved devices.